New drug ZL-1310 tested in patients with Hard-to-Treat cancers

NCT ID NCT06885281

Recruiting now Disease control Sponsor: Zai Lab (Shanghai) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 5 times

Summary

This study tests a new drug called ZL-1310 in adults with advanced neuroendocrine carcinomas (a type of solid tumor) that have worsened after platinum-based chemotherapy. The trial has two parts: Phase 1b checks safety and side effects, while Phase 2 looks at whether the drug shrinks tumors. About 112 participants will receive ZL-1310 and be monitored for response and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ZL-1310
What this could lead to: If it works, this could point toward a new treatment option for people with advanced neuroendocrine carcinomas that have stopped responding to standard chemotherapy.
What could go wrong: This is an early-phase trial (Phase 1b/2) with only 112 participants, so it is too soon to know if ZL-1310 is safe or effective. Side effects are unknown, and the drug may not shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroendocrine carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

Contacts and locations

Locations

Zai Lab Site 1001
RECRUITING

Shanghai, Shanghai Municipality, 200000, China
Zai Lab Site 1002
RECRUITING

Beijing, Beijing Municipality, 100142, China
Zai Lab Site 1004
RECRUITING

Guangzhou, Guangdong, 510080, China
Zai Lab Site 1006
RECRUITING

Changsha, Hunan, 410013, China
Zai Lab Site 1008
RECRUITING

Changchun, Jilin, 130012, China
Zai Lab Site 1009
RECRUITING

Xiamen, Fujian, 361003, China
Zai Lab Site 1012
RECRUITING

Harbin, Heilongjiang, 150081, China
Zai Lab Site 1013
RECRUITING

Beijing, Beijing Municipality, 102200, China
Zai Lab Site 1016
RECRUITING

Guangzhou, Guangdong, 510030, China
Zai Lab Site 1025
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, 200040, China
Zai Lab Site 1026
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, 200433, China
Zai Lab Site 2001
RECRUITING

San Francisco, California, 94143, United States
Zai Lab Site 2002
RECRUITING

New York, New York, 10065, United States
Zai Lab Site 2003
RECRUITING

Dallas, Texas, 75246, United States
Zai Lab Site 2004
RECRUITING

Philadelphia, Pennsylvania, 19111, United States
Zai Lab Site 2006
RECRUITING

Fairfax, Virginia, 22031, United States
Zai Lab Site 2007
RECRUITING

Houston, Texas, 77030, United States
Zai Lab Site 2011
RECRUITING

McAllen, Texas, 78503, United States
Zai Lab Site 2012
RECRUITING

Norfolk, Virginia, 23502, United States
Zai Lab Site 2013
RECRUITING

Detroit, Michigan, 48201, United States
Zai Lab Site 2014
RECRUITING

Nashville, Tennessee, 37203, United States
Zai Lab Site 2015
RECRUITING

Peoria, Illinois, 61637, United States
Zai Lab Site 2024
RECRUITING

Cleveland, Ohio, 44106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.